Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy
Trial ID or NCT#
NCT01450683
Status
NOT RECRUITING
Purpose
This study evaluates if itraconazole causes a reduction in the serum levels of prostate-specific antigen (PSA) in male subjects with castration-resistant prostate cancer (CRPC).
Official Title
A Phase 2 Study of Itraconazole in Castrate-resistant Prostate Cancer Post-chemotherapy
Eligibility Criteria
Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: MALE
Accepts Healthy Volunteers: No
Exclusion Criteria:
Investigator(s)
SandyÌýSrinivas
Medical oncologist,
Urologic specialist,
Genitourinary specialist
Professor of Medicine (Oncology) and, by courtesy, of Urology
Contact us to find out if this trial is right for you.
Contact
ccto-office@stanford.edu
650-498-7061
View on